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Interfractional geometric uncertainties can lead to deviations of the actual delivered
dose from the prescribed dose distribution. To better handle these uncertainties
during the course of treatment, the authors propose a dynamic framework for robust
adaptive radiation therapy in which a variety of robust adaptive treatment strategies
are introduced and evaluated.
This variety is a result of optimization variables with various degrees of freedom
within robust optimization models that vary in their grade of conservativeness. The
different degrees of freedom in the optimization variables are expressed through
either time-and-uncertainty-scenario-independence, time-dependence or time-and-
uncertainty-scenario-dependence, while the robust models are either based on ex-
pected value-, worst-case- or conditional value-at-risk-optimization. The goal of this
study is to understand which mathematical properties of the proposed robust adap-
tive strategies are relevant such that the accumulated dose can be steered as close as
possible to the prescribed dose as the treatment progresses.
We apply a result from convex analysis to show that the robust non-adaptive ap-
proach under conditions of convexity and permutation-invariance is at least as good as
the time-dependent robust adaptive approach, which implies that the time-dependent
problem can be solved by dynamically solving the corresponding time-independent
problem. According to the computational study, non-adaptive robust strategies may
provide sufficient target coverage comparable to robust adaptive strategies if the oc-
curring uncertainties follow the same distribution as those included in the robust
model. Moreover, the results indicate that time-and-uncertainty-scenario-dependent
optimization variables are most compatible with worst-case-optimization, while time-
and-uncertainty-scenario-independent find their best match with expected value op-
timization.
In conclusion, the authors introduced a novel framework for robust adaptive ra-
diation therapy and identified mathematical requirements to further develop robust
adaptive strategies in order to improve treatment outcome in the presence of inter-
fractional uncertainties.
Keywords: Suggested keywords
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I. INTRODUCTION
Adaptive radiation therapy (ART) is a treatment approach where the treatment plan can
be modified in response to patient-specific interfractional geometric variations that could
not have been accounted for during the planning process. Imaging of the daily patient
anatomy and analysis of the impact of anatomical variations on the dose is crucial for
adaptive replanning. Since image guided radiation therapy (IGRT) has been integrated in
daily clinical routine, interfractional variations can be monitored throughout the course of
treatment.
Moreover, the inclusion of patient-specific variations, which are monitored during the
course of treatment, gives the opportunity to provide individualized treatment for each pa-
tient. In recent years, adaptive radiation therapy has been the subject of a number of
clinical and theoretical studies, which demonstrate that this technique can improve treat-
ment outcome1–6. While theoretical studies focus on the problem formulation and choice of
optimization variables, clinical studies improve our understanding of the impact of various
factors on the treatment outcome. The majority of clinical studies have been conducted
on a sample of in-house treated patients with the objective to study the potential benefits
of adaptation through re-optimization7–9 or a plan-of-the-day approach10–12, and how to
make the resulting workload manageable in daily practice. As a consequence, these clinical
studies provide valuable insights on clinical aspects such as realistic adaptation frequency
during the course of treatment and meaningful criteria that trigger adaptation in the event
of non-negligible variations.
However, the treatment plan should also be robust to geometric interfractional uncer-
tainties, such that variations in the delivered dose distribution are small. In conventional
treatment planning, interfractional variations are handled by applying safety margins around
the target and organs-at-risk (OAR) in order to generate plans that are robust to errors.
Usually, safety margins are obtained from population-based recipes based on systematic
and random uncertainties, such as the formulas proposed by van Herk et al.13. Adding these
margins around the clinical target volume (CTV) in order to create the planning target
volume (PTV) thereby increases the treated volume and may consequently increase organ-
and normal tissue toxicity while controlling the tumor dose.
As alternatives to safety margins, various frameworks exploiting robust optimization have
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been proposed14–17 which take into account the possible dose distributions of a priori error
scenarios during the optimization process. These frameworks are based on either expected
value optimization14,15, i.e., minimizing the expected value of the objective function over
the a priori scenario doses, or worst-case-optimization16,17, i.e., minimizing the value of
the objective function of the worst-case scenario. Bokrantz and Fredriksson17 introduced
a scenario-based generalised optimization approach to planning with safety margins, which
implicitly generates a PTV-like volume around the target.
According to these studies14–17, robust target coverage and low OAR doses can be achieved
by incorporating probabilities of error scenarios into the optimization process. Therefore,
combining ART with robust optimization may allow for maintaining high treatment quality
by responding to interfractional geometric variations which could not have been predicted
during the planning process. This assumption has been confirmed in our previously pub-
lished theoretical study18 on robust adaptive radiation therapy strategies, which suggests
that adapting an initial robust plan eventually improves the final therapeutic outcome in
comparison to the non-adaptive conventional approach. Still, further improvements may be
possible through extending the framework to a dynamic adaptive framework.
One of the first adaptive frameworks based on concepts of control theory was introduced
by Lo¨f et al.1, which aims at maximizing the tumor control probability by computing the
optimal corrections to geometric setup errors and random variations in the beam profiles.
The issue of dealing with geometric uncertainties and their impact on the fraction dose has
been addressed by De La Zerda et al.2 who propose a closed-loop control framework for
adaptive radiation therapy, in which radiation plans are reoptimized in response to change
in geometry and thus the delivered dose. Another approach to adaptive radiation therapy,
introduced by Lu et al.3, is designed to adapt the fraction dose in response to the varying
distance between tumor and critical structure. In this particular study, the adapted plans
are generated by solving a dynamic programming problem for each fraction. However, none
of these recently discussed frameworks employ time-and-scenario-dependent optimization
variables, which gives the largest number of degrees of freedom in the optimization vari-
ables. Moreover, the majority of adaptive frameworks in the literature address the issue
of finding the optimal fractionation schedule based on biological models for radiation re-
sponse4–6,19. These publications aim at personalizing the treatment schedule and fraction
size on the basis of the modeled dose response of the tumor and healthy tissue. These
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proposed methods are based on stochastic- and optimal control as proposed by Arcangeli
et al.4, Kim et al.5,6 and Saberian et al.19 in which adaptation is carried out in response to
modeled interfractional variations in the number of tumor cells or varying levels of hypoxia,
respectively. However, radiobiological models are computationally expensive and considered
simplistic, and therefore hardly used in clinical practice20,21.
In this paper, we present a novel dynamic planning framework for robust adaptive ra-
diation therapy in order to handle interfractional geometric variations, which are included
in the robust models as discretized uncertainty scenarios. The novelty of our framework is
the dynamic approach to robust planning for adaptive radiation therapy which uses time-
and/or-scenario-dependent optimization variables combined with various robust models to
design a feedback-control framework such that the robust adaptive plan for the subsequent
fraction is optimized after every fraction in response to the actual delivered dose. As part of
the proposed framework, we evaluate a variety of robust adaptive strategies in order to study
the relationship between robustness and adaptive replanning. This variety of robust adap-
tive strategies is a consequence of choosing different grades of conservativeness and degrees of
freedom of the optimization variables. Concerning the grade of conservativeness, the strate-
gies are based on either expected value-, worst-case-, or conditional-value-at-risk (CVaR)
optimization. The variety in degrees of freedom of the optimization variables stem from us-
ing either time-and-scenario-dependent, time-dependent or time-and-scenario-independent
optimization variables in the robust adaptive strategies. In particular, we want to study
the resulting treatment quality of those strategies which use time-and-scenario-dependent
optimization variables in order to evaluate potential gains from optimizing with respect
to predictions on realized uncertainty scenarios over the whole treatment horizon or shorter
horizons. The latter approach is inspired by model-predictive control (MPC) which is widely
used in signal-processing and chemical engineering22,23, but its characteristic look-ahead fea-
ture has not yet been exploited in adaptive radiation therapy to the best of our knowledge.
Specifically, we utilize this characteristic feature in order to (i) provide predictions of future
accumulated dose over a given finite time horizon and (ii) to compute the optimal adaptive
plan required to steer the predicted system output as close as possible to the pre-set target
value. Since the use of time-and/or-scenario-dependent adaptive plans, i.e. optimization
variables, provides more degrees of freedom compared to conventional non-adaptive plan-
ning, the adaptive plans are expected to perform better in the presence of interfractional
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uncertainties.
The contribution of the mathematical study is the comparative analysis of the mathe-
matical properties of the various robust adaptive and non-adaptive robust strategies, which
provides valuable insights into the potential gains of using time-and/or-scenario dependent
optimization variables over conventional non-adaptive planning. As a consequence, we de-
velop a better understanding of the mathematical requirements for robust adaptive strate-
gies such that significant improvements compared to non-adaptive robust planning can be
expected.
To the best of our knowledge, this work represents the first approach of its kind to
address the mathematical foundation of dynamic planning for robust adaptive radiation
therapy, which introduces a proof-of-concept framework to analyse various robust adaptive
strategies. The framework focuses on handling geometric variations only and at this point
does not take into account radio-biological response. Biologically-based models are hardly
used clinicial routine and should be used with caution20,21. In order to focus on the math-
ematical concepts of the presented framework and reduce computational effort a simplified
one-dimensional model is used. However, this simplified representation contains relevant
aspects of robustness, dynamic planning and treatment plan adaptation providing valuable
insights, which is crucial before applying such a framework to clinical patient data.
II. METHODS
Usually, patients experience interfractional geometric variations throughout the whole
course of treatment. In our proposed framework, interfractional uncertainties are handled
by a variety of robust adaptive strategies. Moreover, we assume to have complete information
on the interfractional uncertainties and their impact on the delivered dose.
II.A. Notation
Throughout this work T denotes the total number of fractions t, while N denotes the total
number of voxels n. The accumulated dose at fraction t is denoted by xt ∈ RN which in our
framework is referred to as the system at the sampling instant t. Since it is assumed that the
patient does not receive any radiation before the start of the treatment at t = 0, the dose x0
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is set to zero. The radiation plan to be applied at t+ 1 is given by ut ∈ RM , where M refers
to the number of bixels. In our framework the plans are referred to as control signals. Dose
deposition is modeled by a dose deposition matrix B ∈ RN×M . In a deterministic setting,
the accumulated dose would be given by xt+1 = xt + But for t = 0, 1, . . . , T − 1. However,
the focus of our framework is on handling interfractional uncertainties. In this work, the
interfractional variations ω are assumed to vary from fraction to fraction and thus, modeled
as independent and identically distributed (i.i.d.) random variables. The uncertainties are
derived from a discretized normal distribution N (0, σ2) and summarized in the set Ω. The
probability of each i.i.d. uncertainty scenario ω ∈ Ω to occur is denoted by pω. The geometric
uncertainty occurring at fraction t is modeled by the stochastic shift matrix S(ωt) ∈ RM×M .
In our framework, the impact of interfractional uncertainties on the fractionated treatment
is modeled by the linear, stochastic, discrete-time state-space dynamics
xt+1 = xt +BS(ωt+1)ut for t = 0, 1, . . . , T − 1. (1)
II.B. Robust Adaptive Strategies
Our proposed framework for robust adaptive radiation therapy uses dynamic optimization
variables in order to deliver the prescribed dose distribution dT in the presence of uncer-
tainties. In this study, the goal is to achieve a uniform dose in CTV and zero elsewhere. In
order to minimize the gap between the accumulated dose xT and the prescribed dose dT , we
choose the quadratic penalty ‖xT − dT‖2, i.e., f
(‖xT − dT‖2) as a planning objective which
is widely used in clinical planning systems, where f refers to the particular robust optimiza-
tion model. A variety of robust adaptive strategies are introduced with the purpose to better
understand how to handle interfractional uncertainties. It is the goal of every robust adap-
tive strategy to generate an individual plan ut at fraction t which is going to be delivered at
fraction t+ 1. The robust adaptive strategies are categorized based on conservativeness, the
degrees of freedom of their optimization variables and their timing for treatment planning.
In order to clearly distinguish between the time instant of plan delivery t and planning, we
introduce the index tP for the latter. The optimization variables ut, i.e., plans are either
i) time-and-scenario-independent, ii) time-dependent or iii) time-and-scenario-dependent.
Time- and scenario-independent optimization variables are used in the non-adaptive robust
strategy, which refers to applying the same plan throughout the course of treatment. Time-
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dependent optimization variables are the basis for the time-varying robust and time-varying
robust adaptive strategy. Time- and scenario-dependent optimization variables are used in
the time- and scenario-dependent robust adaptive strategy and the robust adaptive strate-
gies based on model-predictive control (MPC), referred to as the MPC-strategies. The use of
time- and scenario-dependent optimization variables provides the most degrees of freedom
to mitigate the effect of interfractional uncertainties on the accumulated dose, while time-
and scenario-independent optimization variables provide the least. The performance of the
robust adaptive strategies is analysed in comparison with the corresponding non-adaptive
robust strategy.
As previously discussed, it is the overall goal of all robust strategies introduced in this
framework to minimize the quadratic penalty of the gap between the final accumulated
dose xT = x0 +
∑T−1
τ=0 BS(ωτ+1)uτ and the prescription dose dT , but they all differ in their
approach to generate the plans ut to achieve that goal. Ultimately, it is the objective of
our study to analyse the mathematical properties and performance of the proposed robust
adaptive strategies to solve
min
uτ≥0
f
∥∥∥∥∥xtp +
T−1∑
τ=tP
BS(ωτ+1)uτ − dT
∥∥∥∥∥
2
 ,
s.t. xτ+1 = xτ +BS(ωτ+1)uτ for τ = tP , tP + 1, . . . , T − 1; xtP given,
(2)
where the current system state xtp is assumed to be always known and f refers to the
specific robust model that is combined with a specific treatment strategy. In particular,
we are interested in analysing the performance of combining expected value-, worst-case- or
conditional-value-at-risk (CVaR)-optimization with non-adaptive and adaptive strategies.
II.B.1. Non-adaptive robust strategy
The non-adaptive robust strategy is introduced and evaluated in our proof-of-concept
framework in order to represent the conventional non-adaptive approach to radiation therapy
in which the same plan is delivered at every fraction throughout the course of treatment.
Since it is assumed that information on the accumulated dose xt that could be acquired
during the course of treatment is not included during planning, problem (2) is solved before
the start of the treatment at tP = 0 for positive time- and scenario-independent optimization
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variables uτ = u ≥ 0 ∈ RM ∀τ . The non-adaptive robust strategy is introduced and evaluated
in our framework in order to serve as a lower benchmark which allows us to quantify the
extent of potential improvements of the various proposed robust adaptive strategies which
will be introduced later in this work.
II.B.2. Time-varying robust strategy
In contrast to the non-adaptive robust strategy, the plans in the time-varying robust
strategy may vary from fraction to fraction and therefore, the degrees of freedom of the
optimization variables are increased to include time-dependency, but information on the
current accumulated dose is not taken into account either. Thus, problem (2) is solved
before the start of the treatment at tP = 0 for positive time-dependent optimization vari-
ables uτ ≥ 0 ∈ RM ∀τ . With the time-varying robust strategy, we want to investigate if
adding time-dependency as a degree of freedom to the time-and-scenario-independent op-
timization variables, used in the non-adaptive robust strategy, may give any advantages.
In fact, the move from time- and scenario-independent to time-dependent variables is not
necessary, if (i) the final accumulated dose is evaluated in a quadratic cost function, and if
(ii) the uncertainties that occur at every fraction are assumed to follow the same distribu-
tion. Since conditions (i) and (ii) imply that delivering the mean over all time-dependent
plans at every fraction will be at least as good delivering the time-dependent plans at the
corresponding fraction. In mathematical terms, the choice of the quadratic cost function in
our model gives convexity, while the evaluation of the final accumulated dose affected by
i.i.d. uncertainties represents the permutation-invariance. The mathematical evaluation of
such a case has been analyzed by Parillo24 (p. 100), as reviewed in the following proposition.
Proposition 1 (Parrilo24 (p. 100)). Let f : [U ]→ R be a convex and permutation invariant
function of a convex problem, where [U ] refers to the T-tuple (u0, u1, . . . , uT−1) of vectors ut ∈
RN for t = 0, 1, . . . , T − 1 . Then,
f
([
U¯
]) ≤ f ([U ]) ,
with
[
U¯
]
denoting the T-tuple of the mean 1
T
∑T−1
t=0 ut over all ut for t = 0, 1, . . . , T − 1.
For the sake of completeness, the complete proof is given in appendix B. This result also
indicates that under the conditions of convexity and permutation invariance, the conven-
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tional approach to treatment planning implicitly takes fractionation into account. Therefore,
evaluation and analysis of the final dose distribution for the time-varying robust strategy are
omitted.
II.B.3. Time-varying robust adaptive strategy
In the time-varying robust adaptive strategy, the treatment is designed to generate an
adaptive plan at every fraction tP = t in response to the accumulated dose xt and with
respect to the prescription dose dT and the remaining number of fraction T − t. In contrast
to the previously introduced strategies, planning occurs at every fraction and information
on the accumulated dose is included in the planning process. As a consequence, we solve (2)
at every fraction t after observing xt for the remaining number of fractions T − t. Thus, the
problem to be solved at tP = 0 is equivalent to the time-varying robust and non-adaptive
robust strategy. However, at tP = t, for t = 1, 2, . . . , T − 1, the plans are optimized with
respect to a shrinking treatment horizon T − t. As a consequence of our analysis of the
time-varying robust strategy and Proposition 1, it is sufficient to apply the time-varying
robust adaptive strategy with time-and-scenario-independent optimization variables. In other
words, we solve a problem at every fraction with the same properties as in the non-adaptive
robust strategy, but with respect to a shrinking treatment horizon T − t and accumulated
dose xt.
II.B.4. Time-and-scenario-dependent robust adaptive strategy
In the time-and-scenario-dependent robust adaptive strategy, plans for every fraction t and
possible realization of uncertainty scenarios ω˜T1 = {ω1, ω2, . . . , ωT} over the whole course of
treatment are generated. In other words, at every fraction t an adapted plan is generated
by solving (2) at tP = t in response to the accumulated dose xt and the possible uncertainty
scenarios to occur in the subsequent fractions ω˜Tt+1 = {ωt+1, ωt+2, . . . , ωT}. However, in order
to optimize the plan u0 for the first fraction problem (2) is solved at tP = 0 by taking into
account
∑T
t=1 |Ω|t many possible realizations of uncertainties contained in Ω˜T1 = {Ω × Ω ×
· · · × Ω}, where |Ω| denotes the cardinality of Ω. Thus, the size of the scenario tree grows
exponentially with the number of fractions. In contrast to the time-varying robust adaptive
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strategy, the plans are created to be time-and-scenario-dependent. Therefore, the time-and-
scenario-dependent robust adaptive strategy provides the most degrees of freedom, which
comes at the price of taking into account
∑T
t=1 |Ω|t many realizations during the optimization
of
∑T−1
t=0 |Ω|t many plans at tP = 0 which are going to be applied in the corresponding
scenario tree. As a consequence of using time-and-scenario-dependent variables, obtaining
the optimal set of plans for every possible sequence of uncertainty scenarios may be too
computationally expensive and not even viable for a regular number of fractions. However,
this strategy could be applied to hypofractionated radiation therapy in which the total dose
is administered in fewer fractions and therefore higher fraction doses and which may benefit
to a great extent from adaptive strategies25–27. In general, a compromise between optimality
and computational affordability has to be made.
II.B.5. MPC-strategies
In order to achieve a trade-off between optimality and computational affordability while
using time-and-scenario-dependent variables, we choose to optimize with respect to a relative
to T much shorter planning horizon K. We therefore introduce robust adaptive strategies
which are based on model-predictive control (MPC) in order to take advantage of its look-
ahead-feature in treatment planning. In the MPC-strategies, the adaptive plan is generated
by solving a modified version of (2) at tP = t in which T and dT are replaced by min{T, tP +
K} and min{T,tP+K}
T
dT , respectively. Adaptive plan are optimized throughout the course
of the treatment for t = 0, 1, . . . T − K − 1 in response to the accumulated dose xt and
predictions of the accumulated dose K fractions ahead. Thus, the MPC-strategies require
the computation of at most
∑K
j=1 |Ω|j dose predictions and
∑K−1
j=1 |Ω|j−1 plans, which is lower
than in the time-and-scenario-dependent robust adaptive strategy since K  T . Therefore,
we introduce the MPC-strategies as a clinically and computationally feasible compromise.
In contrast to the previously discussed strategies, we choose to optimize the adaptive plans
with the aim to achieve the modified prescription dose tP+K
T
dT considering the prediction
horizon K. Nevertheless, the adaptive plans could also be generated with respect to the
remaining dose (dT − xtP ) over the remaining number of fractions T − t multiplied by the
length of the shorter horizonK. In this case, T and xtP−dT in (2) are replaced by min{T, tP+
K} and K (dT−xtP )
T−tP , respectively. The evaluation of this modified objective function suggested
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though, that this modified approach may not be superior over our proposed MPC-strategies.
Thus, further evaluation of the modified approach is omitted.
II.C. Robust Models
In section II.B, we introduced various strategies to solve (2) in which f refers to a specific
robust model. In this section, we will discuss the nature of the robust models chosen to
be combined with the non-adaptive and adaptive strategies. Expected value optimization
is the least conservative model, while worst-case-optimization the most conservative; and
conditional-value-at-risk (CVaR)-optimization represents a compromise between the two.
Thus, f
(‖xT − dT‖2) in (2) takes the following form in
1. Expected-value-optimization
E
[‖xT − dT‖2D] , (3)
2. Worst-case-optimization
max
ω˜T1 ∈Ω˜T1
‖xT − dT‖2D (4)
and
3. Conditional-value-at-risk (CVaR)-optimization
min
λ
λ+
1
α
E
[(‖xT − dT‖2D − λ)+] , (5)
where the shorthand z+ and λ denote max {z, 0} and an additional optimization variable,
respectively. The matrix D in (3), (4) and (5) is referred to as the weighting matrix which
will be described in more detail later. In order to avoid discontinuities in the worst-case-
and CVaR- optimization models, the objective functions in (4) and (5) are reformulated as
min
z≥0
{z : z ≥ ‖xT − dT‖2D ∀ ω˜T1 ∈ Ω˜T1 } (6)
and
min
λ,ζ
{λ+ 1
α
pTω˜ζ : λ+ ζω˜ ≥ ‖xT − dT‖2D ∀ω˜T1 ∈ Ω˜T1 , ζ ≥ 0}, (7)
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the max function is substituted, the help variable ζ is introduced and where pω˜ = pω× pω×
· · ·×pω refers to the probability vector for the realizations ω˜T1 . Since the number of possible
realizations of uncertainty scenarios grows exponentially with the number of fractions T ,
problem reformulations may be considered. In case of minimizing the expected value of the
quadratic penalty (3), the optimal solution can be computed in an exact manner independent
of T by exploiting the structure of the quadratic penalty, which is demonstrated in detail
in Appendix A. In worst-case- and CVaR-optimization, an exact optimal solution can be
computed depending on computational power and for a much shorter than conventionally
used treatment length T . In cases such as T = 30, the solution could be optimized based
on Monte Carlo simulated treatments subjected to interfractional uncertainties ω ∈ Ω.
CVaR-optimization can be interpreted as a compromise between expected value- and worst-
case scenario optimization, since its optimal solution minimizes the expected value of the
fraction 0 < α ≤ 1 of the worst scenarios ω ∈ Ω16. Thus, the parameter α which affects
the upper bound of pω controls the grade of conservativeness. The closer α is to 1, the
less conservative the solution will be, while α ≤ minω∈Ω pω with pω > 0 changes (5) to be
equivalent to worst-case-optimization in (4). In this study, α is set to 0.4. The concept of
CVaR-optimization was introduced by Rockafellar and Uryasev28 and it is widely used in
finance for risk management. With reference to robust planning, Fredriksson16 introduced a
framework for robust planning using CVaR to linearly adjust the grade of conservativeness.
For the sake of readability, we introduce the Euclidean norm with respect to the weighting
matrix D in (3), (4) and (5) in order to simplify the extended quadratic penalty function[∑
r∈R
gr
∑
n∈Nr
ηn,rvn,r(xT,n − dT,n)2
]
, (8)
which combines the conventionally used importance weights gr, the relative volumes vn,r
satisfying
∑
n∈Nr vn,r = 1 for each region of interest (ROI) r ∈ R denoting the set of all
regions and the scenario-based voxel weights ηn,r. These scenario-based voxel weights ηn,r
are a result of a generalized scenario-based robust optimization approach to account for
interfractional uncertainties introduced by Fredriksson and Bokrantz17, which omits the
use of CTV-PTV margins. These voxel weights are derived from modeling an uncertainty
scenario ξ ∈ Ξ as whole-body shifts m(ξ) and summarizing the voxels part of the CTV under
scenario ξ in the set C ′(ω) = {n+m(ξ) : n ∈ C}, with C referring to the voxels contained in
the CTV under the scenario of no shift occurring. Thus, the scenario based voxel weights
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are equivalent to the reciprocal number of scenarios ξ under which voxel n is contained in
the scenario-related set C ′(ξ) as expressed by
ηn =
1
|{ξ ∈ Ξ : n ∈ C ′(ξ)}| . (9)
The operator |·| in (9) refers to the cardinality of the set {ξ ∈ Ξ : n ∈ C ′(ξ)} and the scenario-
based voxel weights ηn satisfy the relation 1/|Ξ| ≤ ηn ≤ 1 for every voxel n.
II.D. Geometry
In order to focus on the mathematical properties of the proposed framework, a one-
dimensional patient phantom, as illustrated in Figure 1, is considered. This model schemat-
ically represents a slice of a two-dimensional phantom or an intersection of a sagittal and
transversal cut of a three-dimensional patient-geometry. The one-dimensional phantom ge-
ometry is discretized into 40 voxels. The phantom contains one clinical target volume (CTV)
and two organs at risk (OARs) which are asymmetrically located around the CTV. The
CTV is located between -1.2 and 1.2 cm, while the organs at risk are located in the intervals
[−2,−2.2] cm and [2, 3] cm. The CTV is an extension of the visible tumor and accounts for
the microscopic spread of cancer cells. As a consequence, dose coverage of the CTV during
the whole course of treatment has to be maintained despite the presence of interfractional
variations in order to guarantee a successful treatment outcome. According to our model,
the CTV is irradiated by a perpendicular oriented field, while the absorbed dose in each
voxel is modeled by Gaussian functions at a spacing of 1.5 mm with a standard deviation
of 3 mm, which is represented by the dose-deposition matrix B. As a consequence of the
idealized phantom geometry, the number of bixels M and their positions are assumed to be
identical with the number of voxels N and their location. Thus, the dimensions of the plans,
the shift-matrix and dose-deposition matrix are simplified to ut ∈ RM , S(ω) ∈ RN×M and
B ∈ RM×M , respectively. In consideration of reducing computational effort, interfractional
geometric uncertainties are modeled as rigid whole-body shifts such that the dose received
by each voxel can be computed and tracked in a straightforward manner.
14
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-3 3-2.2 2-1.2 1.2
left OAR CTV right OAR
Fig. 1 One-dimensional patient phantom. The dimensions are given in cm.
II.E. Computational Study
The computational study is performed in MATLAB version 9.1 using the IBM optimiza-
tion solver CPLEX in the studio version 12.6.3. As previously discussed, we assume that the
one-dimensional phantom geometry is subjected to rigid whole-body shifts. These random
shifts ω ∈ Ω are derived from the discretized normal distribution N (0, 0.25), which is in ac-
cordance with clinical studies on interfractional prostate motion29–31. The discretized scenar-
ios ω ∈ Ω are obtained by adapting the normal distribution to the voxel grid according to its
mean and standard deviation18. The set Ω = {−2,−1, 0, 1, 2} which is included in the robust
optimization models contains the uncertainty scenarios measured in voxel shifts with the cor-
responding normalized probabilities pω = {0.0924, 0.2414, 0.3324, 0.2414, 0.0924}, Through-
out all optimization models and treatment strategies the optimization weight gCTV for the
CTV is set to 100, while the weight for the right OAR and left OAR is set to 10 and the
external is set to 1. The study of the proposed framework is conducted in two stages.
First, the feasibility study is carried out in order to study the trade-off between mathemat-
ical optimality and computational feasibility of our proposed framework and the feasibility
of adaptive strategies in hypofractionated radiotherapy. The trade-off is evaluated by com-
paring the objective function values at the optimal solution of every strategy. Among the
presented strategies, the non-adaptive robust strategy is considered the lower benchmark and
the time-and-scenario-dependent strategy the upper benchmark, since it takes into account
uncertainties over the whole treatment horizon. In the mathematical study, the impact of
the choice of optimization variables, i.e.: time-dependent or time-and-scenario-dependent,
on the optimal solution is examined. For the sake of computational tractability, the total
number of fractions T is set to five and the prediction horizon K is set to one, two and
three fractions. As a consequence, the evaluation of the time-varying robust adaptive and
MPC-strategies relative to the robust non-adaptive and time-and-scenario-dependent robust
adaptive strategy is carried out in a fair manner.
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Second, in the conventional fractionation length study we study the performance of our
proposed strategies for a population of 100 treatments, each consisting of 30 fractions with
interfractional uncertainties. These uncertainty scenarios are generated from the same nor-
mal distribution N (0, 0.25) as those accounted for during the optimization process, but
truncated in a different manner in order to test our strategies for a larger set of uncertainty
scenarios {−3,−2,−1, 0, 1, 2, 3}. For the sake of a fair comparison, the robust non-adaptive,
time-varying robust adaptive and MPC-strategies are evaluated for the same treatment pop-
ulation. The plans for the robust non-adaptive and time-varying robust adaptive strategy
combined with worst-case- and CVaR-optimization for T = 30 are computed based on Monte
Carlo simulations, as explained previously. In order to investigate the statistical accuracy
and confirm the predictive value of our study, the framework is evaluated for two addi-
tional populations with 150 and 200 treatments. From all three populations, the total sum
of squares of voxel dose deviations from the prescribed dose and root mean square errors
are obtained and compared with each other. Since these values are of the same order of
magnitude, we conclude that the population of 100 treatment is sufficiently large.
III. RESULTS
III.A. Feasibility Study
In the feasibility study, the objective function value for every robust strategy is evalu-
ated at its respective optimal solution and summarized in table I for a mathematical and
objective analysis of the proposed strategies. We quantify to which extent the objective
function values of the various robust adaptive strategies decrease in comparison with the
corresponding non-adaptive robust strategy as the degrees of freedom in the optimization
variables increase. Thus, the comparison is performed among the strategies and not among
the robust models. Moreover, we investigate how well the MPC-strategies approximate
the time-and-scenario-dependent strategy. The objective function values of the time-and-
scenario-dependent strategy in combination with CVaR-optimization could not be computed
because of computational issues related to limited memory, which underlines the importance
of approximation methods, e.g. MPC. Overall, the evaluation of objective function values
indicates a number of trends.
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First, the objective function values of the robust adaptive strategies are lower than those
of the respective non-adaptive strategy, which confirms the property of the non-adaptive
robust strategy as the lower benchmark and the time-and-scenario-dependent strategy as the
upper benchmark in the context of mathematical accuracy. Second, the adaptive strategies
which consider uncertainties over a prediction horizon larger than one fraction, i.e., the time-
varying robust adaptive, MPC2- and MPC3-strategies achieve lower objective function values
than the MPC1-strategy, which indicates a likely benefit of taking into account possible
uncertainties over a prediction horizon K > 1. The decrease of objective function value in
the time-and-scenario-dependent and MPC-strategies stems from optimizing the plans u0
and ut with respect to possible realizations of uncertainty scenarios over the horizon T
or K. However, there is a risk of overcompensation relative to the prescribed fraction
dose dT
T
. Therefore, we introduce stabilizing constraints to keep the fraction dose within the
interval (1 − γ)dT
T
≤ Buτ ≤ (1 + γ)dTT , where γ ≥ 0 specifies the user-defined lower and
upper thresholds for ut. In our framework, γ is set to 0.05. The nature of overcompensation
is discussed later in this section. The trend of decreasing objective function values continues
for the stabilized time-and-scenario-dependent- and MPC-strategies as illustrated in table I,
even though it is less pronounced since the stabilizing constraints decrease the feasible
region. However, in case of combining CVaR optimization with the MPC1-strategy this
trend may not be as strong as in the other robust models, since its objective function value
is slightly larger than that of the non-adaptive robust strategy. Third, the combination of
worst-case-optimization with the time-and-scenario-dependent- and MPC-strategy seems to
lead to the largest improvement in objective function value from the non-adaptive strategy.
Thus, worst-case-optimization may be most compatible with time-and-scenario-dependent
variables. It should be pointed out that the MPC-strategies are approximations of the
time-and-scenario-dependent strategy and that the objective function values are computed
from all |Ω|T attainable final dose distributions and therefore, small differences in objective
function values should be interpreted in relative terms.
In terms of evaluating the resulting treatment quality throughout a hypofractionated
treatment, we gain the following insights. First, the non-adaptive robust and time-
varying robust adaptive strategy generate quite uniform dose profiles, as illustrated in
Figures 2(a), 2(b), 2(c) and 2(d). The x-axis represents the one-dimensional phantom
where the location of the CTV and OARs is indicated through vertical separation lines.
17
Boeck et al.
Table I Evaluation of the final doses x5 in all models and strategies for |Ω| = 5 and number of
voxels N = 40. ∗) The optimal solution of the time-and-scenario-dependent strategy combined with
CVaR-optimization could not be computed due to computational limitations.
non-adaptive
time-varying
adaptive
MPC1 MPC2 MPC3
time- & scenario
dependent
E 0.2086 0.1868 0.1991 0.1794 0.1743 0.1729
stabilized E n/a n/a 0.2097 0.2013 0.2003 0.2002
worst-case 0.4832 0.3413 0.3431 0.3179 0.3058 0.2977
stabilized worst-case n/a n/a 0.3479 0.3278 0.3198 0.3167
CVaR 0.2552 0.2371 0.2575 0.2302 0.2195 −∗)
stabilized CVaR n/a n/a 0.2606 0.2445 0.2411 −∗)
The dose levels of the realized accumulated dose distributions and plans are given along
the y-axis, ranging from 0 to 1.2 relative to the prescriptions dose level 1. The most
likely accumulated dose realization in every fraction is indicated in black, while the re-
alizations within one standard deviation are visualized in dark grey. The remaining less
likely realizations are shown in light grey. Second, the plans obtained from the time-varying
robust adaptive strategy in combination with expected-value-optimization become less uni-
form as the treatment progresses and the time horizon (T − t) shrinks, as demonstrated
in Figure 2(b). These plans are optimized in an exact manner by taking advantage of
the structure of the expected quadratic penalty, as demonstrated in Appendix A, which
leads to a linear and quadratic dependency on the shrinking time horizon in the Hes-
sian (T − t)E [STBTDBS] + (T − t)(T − t − 1)E[S]TBTDBE[S] of (3). Thus, as the
plans for the last fractions are computed, the contribution of the squared mean value
of (T − t)(T − t − 1)E[S]TBTDBE[S] decreases and eventually disappears for t = T − 1.
Therefore, the plans become less uniform because the term (T − t)E [STBTDBS] squares
the impact of the uncertainties modelled by the shift matrix S. Since this is a result of
minimizing the expected quadratic penalty, the dose profiles obtained from the time-varying
adaptive strategy combined with worst-case- and CVaR-optimization remain uniform, as
illustrated in Figure 2(c) and 2(d), respectively. CVaR-optimization is a compromise be-
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(a)Fraction and
accumulated dose for
the non-adaptive
robust stratetegy
combined with
E-optimization.
(b)Fraction and
accumulated dose for
the time-varying
adaptive strategy
combined with
E-optimization.
(c)Fraction and
accumulated dose for
the time-varying
adaptive strategy
combined with worst-
case-optimization.
(d)Fraction and
accumulated dose for
the time-varying
adaptive strategy
combined with
CVaR-optimization.
Fig. 2 Evaluation of the fraction doses and accumulated dose xt+1 for t = 0, . . . , T −1 throughout
the course of treatment with T = 5 fractions in comparison with the prescribed fraction dose tdTT for
the stabilized non-adaptive robust and time-varying adaptive strategy. The most likely realization
of xt+1 is represented by the solid black line, while the realizations within one standard deviation
are visualized in dark grey.
tween expected-value- and worst-case-optimization in terms of conservativeness which is
reflected in the shape of the resulting dose profiles. Third, the plans obtained from the
time-and-scenario-dependent robust adaptive and the MPC-strategies are optimized in order
to account for the possible realizations of uncertainty scenarios over the horizon T or K,
which may cause overcompensation as mentioned earlier. The order of magnitude of over-
compensation seems to correlate with the planning horizon T and K. We observe that the
longer the planning horizon, the larger the overcompensation will be at the edges of the
CTV which are most likely to be affected by interfractional uncertainties, as illustrated in
Figure 3(a) and 3(b) for the combination of expected value-optimization with time-and-
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(a)Fraction and accumulated dose
for the unstable
time-and-scenario-dependent
robust adaptive strategy combined
with E-optimization.
(b)Fraction and accumulated dose
for the unstable MPC-strategy
with K = 3 combined with
E-optimization.
(c)Fraction and accumulated dose
for the unstable MPC-strategy
with K = 3 combined with
worst-case-optimization.
Fig. 3 Evaluation of the fraction doses and accumulated dose xt+1 for t = 0, . . . , T −1 throughout
the course of treatment with T = 5 fractions in comparison with the prescribed fraction dose tdTT
for the unstable time-and-scenario-dependent robust adaptive and MPC-strategies with K = 3.
The most likely realization of xt+1 is represented by the solid black line, while the realizations
within one standard deviation are visualized in dark grey.
scenario-dependent strategy and the MPC-strategy with K = 3, respectively. In expected
value optimization, the overcompensation takes shape in the form of overdose at the edges
of the CTV. In worst-case-optimization, the impact of future uncertainties is handled by a
flat dose-fall-off at the edges in order to reduce the risk to the nearby OARs in the event
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(a)Fraction and accumulated dose
for the stabilized
time-and-scenario-dependent
robust adaptive strategy combined
with E-optimization.
(b)Fraction and accumulated dose
for the stabilized MPC-strategy
with K = 3 combined with
E-optimization.
(c)Fraction and accumulated dose
for the stabilized MPC-strategy
with K = 3 combined with
worst-case-optimization.
Fig. 4 Evaluation of the accumulated dose xt+1 and plans ut for t = 0, . . . , T − 1 throughout the
course of treatment with T = 5 fractions in comparison with the prescribed fraction dose tdTT for
the stabilized time-and-scenario-dependent robust adaptive and MPC-strategies with K = 3. The
most likely realization of xt+1 is represented by the solid black line, while the realizations within
one standard deviation are visualized in dark grey.
of the largest uncertainty, as shown in Figure 3(c). Furthermore, worst-case-optimization
results in a smaller spread of the various realized accumulated dose distributions xt+1. As a
result of the stabilizing constraints, the accumulated doses and plans are more uniform, as
illustrated in Figure 4(a), 4(b), and 4(c). Moreover, the spread of dose realizations around
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the most likely outcome is decreased. In the non-adaptive robust and time-varying robust
adaptive strategy, the stabilizing constraints are not imposed since these strategies generate
plans which do not exceed the prescribed fraction dose across the whole CTV.
III.B. Conventional fractionation length study
In the conventional fractionation length study, we evaluate the interplay between ro-
bustness and non-adaptive and adaptive strategies for a conventionally long treatment
with 30 fractions. The performance of the non-adaptive robust, time-varying robust adap-
tive, MPC1-, MPC2- and MPC3-strategy combined with expected value-, worst-case- and
CVaR-optimization is measured by evaluating their final dose distribution xT for a popula-
tion of 100 treatments with predictable interfractional uncertainties.
Their performance in terms of CTV-coverage under uncertainty is illustrated by dose-
probability histograms in Figure 5. The dose-probability histograms show the probability
that the final accumulated dose distribution xT provide CTV-coverage in accordance with
the ICRU guidelines32 which recommend that 99% of the CTV should receive at least 95%
of prescription dose. The probability that 99% of the CTV will receive at least a certain
dose level or above is plotted on the y-axis. In order to facilitate the analysis of the perfor-
mance of the various robust non-adaptive and adaptive strategies, the recommended dose
level of 95% of the prescription dose is displayed in Figure 5. According to the results
illustrated in Figures 5(a), 5(b) and 5(c), the majority of strategies and robust models ap-
pear to provide sufficient target coverage as given by the ICRU-guidelines with similarly
high probability. This result indicates that robust optimization in combination with the
conventional non-adaptive strategy ensures CTV-coverage, if the uncertainties occurring
throughout the course of treatment are predicted correctly and are included in the robust
optimization problem. Among the investigated robust models, worst-case-optimization may
be the most favourable model to be combined with the non-adaptive treatment approach,
as demonstrated in Figure 5(b).
Concerning the interplay between robust models and the adaptive strategies, expected
value optimization seems to be a good match for the time-varying robust adaptive strategy,
which achieves target coverage with the highest probability compared to the MPC-strategies,
as shown in Figure 5(a). According to our evaluation of CTV-coverage probability for the
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Fig. 5 Evaluation of the final dose xT in the CTV for the robust models and adaptive strategies
by using dose-probability-histograms to compare the probability that 99% of the CTV receives a
certain percentage of the prescription dose or higher after exposure to predictable uncertainties.
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Fig. 6 Evaluation of the 90th percentile of the final dose xT in the right OAR over all simulated
treatments exposed to interfractional uncertainties. during treatments following the non-adaptive
and adaptive strategies combined with expected value- and worst-case-optimization model.
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various robust strategies combined with expected value optimization in Figure 5(a), the
MPC-strategies which are based on time-and-scenario optimization variables may not be as
a good match for expected value optimization as the time-varying robust adaptive strategy.
However, it should be noted that the MPC-strategies are approximative methods in contrast
to the time-varying adaptive strategy, which in combination with expected value optimization
gives exact solutions. Since the expected value over the anticipated scenarios gives little
weight to extreme scenarios with a low probability, the use of time-and-scenario-dependent
optimization variables may not be suitable. On the other hand, time-and-scenario-dependent
optimization variables appear to be good combination for the more conservative optimization
models as shown in Figure 5(b) and 5(c) according to which the MPC-strategies provide
target coverage with the highest probability. In the linear formulations of our worst-case-
and CVaR-optimization problems (7) and (6), every realization of uncertainty scenarios
is represented by a corresponding constraint. Time-and-scenario-dependent optimization
variables seem to exploit this feature and thus, the additional computational effort may be
worthwhile in the case of combining MPC-strategies with conservative robust optimization
models. Based on the observation that all MPC-strategies show very similar trends in terms
of CTV-coverage, the most suitable prediction horizon cannot be clearly identified. The
similarity of these trends among the MPC-strategies may be caused by their rather short
prediction horizons relative to the treatment length of 30 fractions.
Concerning the risk of high dose exposure in the OAR, the accumulated dose in the OARs
is evaluated by evaluating the dose levels of the 90th percentile over the 100 treatments. We
evaluate the 90th percentile in order to visualize the order of magnitude of an upper dose
threshold for 90% of the treatments with the robust optimization models which according
to our framework are most likely to provide sufficient CTV-coverage. Since the right OAR
is closer to the CTV, it may likely receive a higher dose than the left OAR in the event
of interfractional uncertainties. Since expected value- and worst-case-optimization appear
to provide the highest probability of CTV-coverage, we choose to draw attention to their
impact on the right OAR. The voxels of the right OAR which are in proximity to the CTV
receive the largest amount of dose as shown in Figure 6(a) and 6(b), which illustrate the 90th
percentile for each voxel in the right OAR after 100 treatments. In case of expected value
optimization, the time-varying robust adaptive strategy leads to the least dose exposure to
the right OAR among the adaptive strategies, but its dose levels are comparable to those of
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non-adaptive strategy. Since the combination of the time-varying robust adaptive strategy
with expected value optimization gives the highest probability of CTV-coverage, we may
conclude that a robust adaptive strategy based on expected value optimization may be most
effective with time-and-scenario-independent optimization variables. In case of worst-case-
optimization, all strategies lead to similar upper dose levels in the right OAR, indicating
that robust adaptive strategies may not increase the risk of high dose exposure to the
OARs. Moreover, the upper dose thresholds of the accumulated dose in the right OAR are
higher than in combination with expected value optimization. However, these differences
between non-adaptive and adaptive strategies and the robust models are rather small since
the simulated treatments follow the same distribution as those included in the robust models.
Overall, we conclude that if the treatment is supposed to be adaptive with a high adapta-
tion frequency throughout the course of treatment , it may be the most beneficial to combine
expected value optimization with time-and-scenario-independent optimization variables. If
however, the treatment is supposed to be executed in a non-adaptive manner or only adaptive
in rare cases, a more conservative model in combination with time-and-scenario-dependent
optimization variables may be recommended.
IV. DISCUSSION
In this study, a proof-of-concept framework is presented which handles interfractional
variations by employing various robust adaptive strategies based on either time-and-scenario-
independent, time-dependent or time-and-scenario-dependent optimization variables which
are combined with expected value-, worst-case- or CVaR-optimization. The various strate-
gies are evaluated and compared with each other based on their performance to mitigate the
impact of uncertainties on the accumulated dose and their ability to steer the accumulated
dose as close as possible to the prescribed dose distribution. In particular, we evaluate the
potential benefits of increasing the degrees of freedom in the optimization variables and
their interplay with robust optimization models with varying grades of conservativeness.
Furthermore, we investigate the performance of our framework in a hypofractionated and
conventionally long radiotherapy treatment. In order to conduct the comparative analysis
of the various strategies in a fair manner, all strategies are exposed to the same set of inter-
fractional uncertainty scenarios. In the analysis of our framework in the hypofractionated
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treatment, the objective function values of the robust adaptive strategies at their optimal
solutions are computed and as a consequence, conclusions are drawn based on objective
criteria. In the analysis of our framework in the conventionally long treatment, the final ac-
cumulated dose distributions for the various robust non-adaptive and adaptive strategies are
evaluated in terms of CTV-coverage probability and high dose exposure to the right OAR
after 100 simulated treatments in the presence of interfractional uncertainties. Overall, we
gain the following insights. First, we learn from the analysis of the non-adaptive and time-
varying robust strategy, that a time-dependent problem can be solved in an optimal manner
by solving the corresponding problem with time-independent optimization variables. Thus,
we can implement an adaptive treatment strategy by dynamically solving a sequence of
time-independent problems as is the case in the time-varying adaptive strategy. This finding
is especially relevant in a clinical context since it implies that adaptive radiation therapy
can become part of clinical practice using commercially available treatment planning soft-
ware. Second, we learn that time-and-scenario-dependent optimization variables, used in
the time-and-scenario-dependent robust adaptive and MPC-strategies in order to account
for dose predictions, are most compatible with conservative robust optimization models
and that including dose predictions potentially improves treatment quality compared to the
non-adaptive treatment approach. Third, we learn if the uncertainties occurring during
treatment coincide with those included in the robust optimization models, our non-adaptive
robust strategies give high probability of sufficient CTV-coverage without putting the OARs
at greater risk. This finding implies that the robust non-adaptive approach leads to a suc-
cessful treatment for that group of patients whose interfractional uncertainties have been
predicted correctly. Among the evaluated robust models, worst-case-optimization may be
the most suitable match for the non-adaptive strategy. Fourth, we learn that an adaptive
strategy intended for daily adaptation does not require a very conservative robust optimiza-
tion model in order to provide sufficient CTV-coverage. In case the robust model is based
on expected-value-optimization, our study suggests that time-and-scenario-independent op-
timization variables may be most compatible.
Throughout this work, the emphasis is put on the mathematical properties of the proposed
strategies and understanding the role of robust optimization in adaptive radiation therapy.
The insights gained from the mathematical evaluation and Proposition 1 are geometry-
independent, since the system dynamics and robust optimization problems can be applied
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to two- or three-dimensional geometries. In the computational study however, we consider a
one-dimensional patient phantom1,18 and subjected it to interfractional variations which are
modeled as rigid whole-body shifts13,16,18 in order to reduce computational effort. The as-
sumption of having i.i.d. shifts is reasonable for random setup errors and organ motion13–16.
Moreover, the evaluation of our proposed framework in an idealized model gives the op-
portunity to solely focus on their mathematical properties and to better understand the
interplay between robustness and the various non-adaptive and adaptive strategies. Gaining
insight into the role of the problem formulation is critical before applying our framework to
clinical patient data. Evaluating our framework first on clinical patient data would make it
more challenging to identify the generic properties of the proposed framework, since they
could potentially coincide with a specific anatomy or beam setup. Since our framework is
evaluated on a simplified geometry, the differences between the various strategies might be
more or less pronounced for a two- or three-dimensional geometry. As a consequence of as-
suming i.i.d. interfractional uncertainties, complete information about the accumulated dose
and no costs associated with plan adaptation, the results of our study should be interpreted
in relative terms.
Overall, this study provides mathematical insights into the requirements and suitable
set up for a robust adaptive framework necessary to further develop our framework to
include more complex model assumptions such as organ deformation and adapting the robust
optimization model in response to unpredictable uncertainty scenarios. To the best of our
knowledge, this is the first study of its kind to address the mathematical properties required
for robust adaptive radiation therapy. Thus, this work represents a fundamental study which
gives the opportunity to further study robust adaptive radiation therapy planning.
V. CONCLUSION
In this paper, we introduce a dynamic planning framework to handle interfractional
geometric variations in which robust adaptive strategies with varying degrees of freedom and
grade of conservativeness are presented and evaluated. The motivation behind introducing
and analysing such a wide range of robust adaptive strategies is to better understand how
to generate the right plan for every fraction in the event of interfractional uncertainties in
order to mitigate their impact on the accumulated dose distribution throughout the course
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of treatment. Therefore, a mathematical and computational study is carried out in order
to study the implications of combining robust optimization models with adaptive radiation
therapy strategies in the context of a hypofractionated and conventionally long radiotherapy
treatment.
From our study we gain insights on the strengths of using time-and-scenario-independent
optimization variables in robust adaptive planning and in combination with robust non-
adaptive treatment strategies. Under the model assumptions of optimizing the final accu-
mulated dose in the presence of i.i.d. interfractional uncertainties, the optimal plan for a
time-varying planning approach can be obtained by dynamically solving the corresponding
problem with time-and-scenario-independent optimization variables. In non-adaptive robust
planning, the achieved treatment quality is comparable to that of the robust adaptive strate-
gies, if the actually occurring interfractional uncertainties coincide with those accounted for
in the robust plan. In terms of the interplay between robustness and adaptive planning, we
learn that time-and-scenario-dependent optimization variables may be most compatible with
worst-case-optimization in order to benefit the most from dose predictions in the adaptive
plans, while expected value optimization does not benefit from time-and-scenario-dependent
optimization variables to the same extent.
The clinical value of our proposed framework is the insight into the strengths and weak-
nesses of the conventional non-adaptive approach in combination with robust optimization
models, and in which cases and ways robust adaptive strategies can be used to further
improve treatment outcome. Overall, based on the findings of this work we have a bet-
ter understanding about the requirements on the degrees of freedom of the optimization
variables and their interplay with robust optimization models, which is crucial for further
development of planning frameworks for robust adaptive radiation therapy in order to man-
age various types of interfractional uncertainties experienced by patients.
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Appendix A: Reformulation of the expected quadratic penalty
In the case of minimizing the expected value of
∥∥∥x0 +∑T−1t=0 BS(ωt+1)u− dT∥∥∥2
D
can be
formulated as follows
E[
T−1∑
t=0
‖xt +BS(ωt+1)u− dT‖2D] =
|Ω|∑
t1=1
pt1
|Ω|∑
t2=1
pt2 · · ·
|Ω|∑
tT=1
ptT (x0 +BS(ωt1)u+BS(ωt2)u+ · · ·+BS(ωtT )u− dT )T
D (x0 +BS(ωt1)u+BS(ωt2)u+ · · ·+BS(ωt2)u− dT ) =
|Ω|∑
t1=1
pt1
|Ω|∑
t2=1
pt2 · · ·
|Ω|∑
tT=1
ptT
[
uTST (ωt1)B
TDBS(ωt1)u+ u
TST (ωt2)B
TDBS(ωt2)u+ · · ·
+ uTST (ωtT )B
TDBS(ωtT )u+ u
TST (ωt1)B
TDB (S(ωt2) + · · ·+ S(ωtT ))u
+uTST (ωt2)B
TDB (S(ωt1) + S(ωt3) + · · ·+ S(ωtT ))u+ · · ·
+uTST (ωtT )B
TDB
(
S(ωt1) + S(ωt2) + · · ·+ S(ωtT−1)
)
u
+2(x0 − dT )TD (BS(ωt1) +BS(ωt2) + · · ·+BS(ωtT ))u+ (x0 − dT )TD(x0 − dT )
]
According to our model assumptions of i.i.d interfractional uncertainties ω ∈ Ω,
• ∑|Ω|ti=1 ptiS(ωti) = ∑|Ω|tj=1 ptjS(ωtj) = E[S] ∀i, j = 1, 2, . . . , T where i 6= j,
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• ∑|Ω|ti=1 ptiS(ωti)TBTDBS(ωti) = ∑|Ω|tj=1 ptjS(ωtj)TBTDBS(ωtj) = E[STBTDBS] ∀i, j =
1, 2, . . . , T where i 6= j, and
• ∑|Ω|ti=1 ptiS(ωti)TBTDB∑|Ω|tj=1 ptjS(ωtj)T = ∑|Ω|tj=1 ptjS(ωtj)TBTDB∑|Ω|ti=1 ptiS(ωti)T =
E[S]TBTDBE[S] ∀i, j = 1, 2, . . . , T where i 6= j,
the expected quadratic penalty can be written as the following quadratic optimization prob-
lem
uT
(
TE[STBTDBS] + T (T − 1)E[S]TBTDBE[S])u+2T (x0−dT )TDBE[S]u+(x0−dT )TD(x0−dT ).
(A1)
Appendix B: Proof of Proposition 1
Proof. Since f is permutation invariant, i.e., under a permutation pi : [U ] → [U ], the value
of the function f remains unchanged f ([U ]pi) = f([U ]). Moreover, f is convex and by
using Jensen’s inequality for convex functions of x1, x2, . . . , xn with weights λi ≥ 0, i =
1, . . . , n,
∑n
i=1 λi = 1,
f
(
n∑
i=1
λixi
)
≤
n∑
i=1
λif(xi),
the convex combination of all possible permutations pi : [U ]→ [U ] of the T-tuple [U ] gives
f
(
1
T !
T !∑
k=1
[U ]pik
)
≤ 1
T !
T !∑
k=1
f([U ]pik).
Since f is permutation invariant, we get for the right-hand side that
T !∑
k=1
f([U ]pik) = T !f([U ]).
The argument of f on left-hand side gives the mean over all elements in the T-tuple [U ] for
every combination k,
1
T !
T !∑
k=1
[U ]pik =
1
T !
T !∑
k=1
(u0, u1, . . . , uT−1)
pik =
(T − 1)!
T !
(
T−1∑
k=0
uk,
T−1∑
k=0
uk, . . . ,
T−1∑
k=0
uk
)
.
Thus, the left-hand side is a T-tuple of the mean over all vectors uk for k = 0, 1, . . . , T − 1,
f
(
1
T !
T !∑
k=1
[U ]pik
)
= f
(
1
T
(
T−1∑
k=0
uk,
T−1∑
k=0
uk, . . . ,
T−1∑
k=0
uk
))
= f
([
U¯
])
.
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Combining the reformulated forms of the right-hand and left-hand side we have that
f
([
U¯
]) ≤ f ([U ]) ,
which proves the proposition.
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